Cargando…

Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic

BACKGROUND AND OBJECTIVES: Cebranopadol is a novel first-in-class analgesic acting as a nociceptin/orphanin FQ peptide and opioid peptide receptor agonist with central analgesic activity. It is currently in clinical development for the treatment of chronic pain conditions. This trial focuses on the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kleideiter, Elke, Piana, Chiara, Wang, Shaonan, Nemeth, Robert, Gautrois, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766727/ https://www.ncbi.nlm.nih.gov/pubmed/28623508 http://dx.doi.org/10.1007/s40262-017-0545-1

Ejemplares similares

Correction to: Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic
por: Kleideiter, Elke, et al.
Publicado: (2018)

Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study
por: Göhler, Karin, et al.
Publicado: (2019)

Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial
por: Christoph, Annette, et al.
Publicado: (2017)

Cebranopadol: A First-in-Class Nociceptin Receptor Agonist for Managing Chronic Pain
por: Nair, Abhijit S, et al.
Publicado: (2020)

A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism
por: Fantinati, Anna, et al.
Publicado: (2017)

Effects of Cebranopadol on Cocaine-induced Hyperactivity and Cocaine Pharmacokinetics in Rats
por: Wei, Huimei, et al.
Publicado: (2020)

Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist
por: Rizzi, Anna, et al.
Publicado: (2016)

Cebranopadol as a Novel Promising Agent for the Treatment of Pain
por: Ziemichod, Wojciech, et al.
Publicado: (2022)

Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model
por: Christoph, Thomas, et al.
Publicado: (2018)

Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors
por: Shen, Qianwei, et al.
Publicado: (2017)

Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study
por: Na, Joo Young, et al.
Publicado: (2022)

Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain
por: Sałat, Kinga, et al.
Publicado: (2017)

Influence of Differing Analgesic Formulations of Aspirin on Pharmacokinetic Parameters
por: Kanani, Kunal, et al.
Publicado: (2015)

Subtypes in Patients Taking Prescribed Opioid Analgesics and Their Characteristics: A Latent Class Analysis
por: Rauschert, Christian, et al.
Publicado: (2022)

Long-Acting Opioid Analgesics for Acute Pain: Pharmacokinetic Evidence Reviewed
por: Tyler, Betty M., et al.
Publicado: (2023)

Multiple Dose Pharmacokinetics of Tapentadol Oral Solution for the Treatment of Moderate to Severe Acute Pain in Children Aged 2 to <7 Years
por: Jończyk, Renata, et al.
Publicado: (2022)

Characteristics of Analgesic Patch Formulations
por: Nalamachu, Srinivas, et al.
Publicado: (2020)

FIRST REPORTS OF CLINICAL PHARMACOKINETICS IN NIGERIA
por: Michael, O.S.
Publicado: (2015)

Novel Analgesics with Peripheral Targets
por: Ciotu, Cosmin I., et al.
Publicado: (2020)

Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers
por: Hodges, Michael R., et al.
Publicado: (2023)

Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis
por: Comi, Eleonora, et al.
Publicado: (2017)

Novel αO-conotoxin GeXIVA[1,2] Nonaddictive Analgesic with Pharmacokinetic Modelling-Based Mechanistic Assessment
por: Zhu, Xiaoyu, et al.
Publicado: (2022)

1157. Clinical Safety, Efficacy, and Pharmacokinetics of Fosmanogepix, a Novel First-in-class Antifungal, in Patients with Renal Insufficiency: Subset Analysis from a Phase 2 Candidemia Trial
por: Bulpa, Pierre, et al.
Publicado: (2020)

New Insights into the Opioid Analgesic Profile of cis-(−)-N-Normetazocine-derived Ligands
por: Costanzo, Giuliana, et al.
Publicado: (2023)

A tetrapeptide class of biased analgesics from an Australian fungus targets the µ-opioid receptor
por: Dekan, Zoltan, et al.
Publicado: (2019)

Pharmacokinetic profile of injectable tramadol in the koala (Phascolarctos cinereus) and prediction of its analgesic efficacy
por: Kimble, Benjamin, et al.
Publicado: (2021)

Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain
por: Turnaturi, Rita, et al.
Publicado: (2022)

Investigation of preclinical pharmacokinetics of N-demethylsinomenine, a potential novel analgesic candidate, using an UPLC-MS/MS quantification method
por: Yu, Lulu, et al.
Publicado: (2023)

Tapentadol hydrochloride: A novel analgesic
por: Singh, Dewan Roshan, et al.
Publicado: (2013)

The search for novel analgesics: targets and mechanisms
por: Yaksh, Tony L., et al.
Publicado: (2015)

The Role of Toxins in the Pursuit for Novel Analgesics
por: Maatuf, Yossi, et al.
Publicado: (2019)

Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management
por: Feng, Xiu-qin, et al.
Publicado: (2017)

Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial
por: Steagall, Paulo Vinicius, et al.
Publicado: (2020)

Low Molecular Weight Opioid Peptide Esters Could be Developed as a New Class of Analgesics
por: Goldberg, Joel S.
Publicado: (2011)

Virus variant-specific clinical performance of a SARS-CoV-2 rapid antigen test with focus on Omicron variants of concern
por: Bornemann, Linus, et al.
Publicado: (2023)

Cardiopulmonary Effects and Pharmacokinetics of Dexmedetomidine Used as an Adjunctive Analgesic to Regional Anesthesia of the Oral Cavity with Levobupivacaine in Dogs
por: Pavlica, Matic, et al.
Publicado: (2022)

Use of physiologically‐based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity
por: Gerhart, Jacqueline G., et al.
Publicado: (2022)

Pharmacogenomics and Opioid Analgesics: Clinical Implications
por: Yiannakopoulou, Eugenia
Publicado: (2015)

Evaluation of the Population Pharmacokinetic Properties of Lidocaine and its Metabolites After Long-Term Multiple Applications of a Lidocaine Plaster in Post-Herpetic Neuralgia Patients
por: Bursi, Roberta, et al.
Publicado: (2017)

Cardiorenal Safety of OTC Analgesics
por: White, William B., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o49s34ve2d7f6qbimtooloqu46